Recent research published in The BMJ indicates that high doses of psilocybin, the active component in magic mushrooms, may alleviate depressive symptoms comparably to the commonly prescribed SSRI escitalopram, although the effect size is deemed small. The systematic review and meta-analysis included data from nearly 3,000 participants across 20 trials, highlighting that while psilocybin outperformed placebo, flaws in study designs may have inflated the perceived efficacy of psychedelics. Researchers observed that only one direct trial compared psilocybin to escitalopram, underlining the limited data on this psychedelic treatment. Despite promising findings, the subjective nature of psychedelic experiences complicates the isolation of their direct effects from the psychological support often provided during treatment. As interest in psychedelic medicine grows, experts note the importance of further investigation into psilocybin's safety and effectiveness as a treatment for depression. The study contributes to the evolving conversation about integrating psychedelics into mainstream psychiatric care, amidst ongoing debates over their safety and efficacy.